DVA.NYSEDavita INC

Form 4: DaVita Director Acquires 332 Shares

Sentiment:

Insider Transaction Report


DaVita Inc. Director Phyllis R. Yale acquired 332 shares of common stock on March 15, 2026, as part of a pre-arranged plan.

Summary

  • Phyllis R. Yale, a Director of DaVita Inc. (DVA), acquired 332 shares of common stock.
  • The transaction occurred on March 15, 2026.
  • The shares were acquired at a price of $0, indicating a grant or award rather than a purchase.
  • Following this transaction, Ms. Yale directly beneficially owns 14,313 shares of DaVita Inc. common stock.
  • The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake, even through a grant, aligns their interests with shareholders and suggests confidence in the company's long-term value.

Positives

  • An insider (Director) is increasing their ownership in the company, which can be seen as a vote of confidence in the company's future.
  • The acquisition was part of a Rule 10b5-1 plan, indicating a pre-planned, non-discretionary transaction, which often reduces concerns about opportunistic trading.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider acquisitions, especially by directors, are often viewed positively by the market as they signal confidence in the company's future prospects, aligning management interests with shareholders. This is a routine disclosure for executive compensation or board member grants within the healthcare services industry.

Comparison to Industry Standards

  • Insider ownership levels vary across industries and companies. While 14,313 shares for a director is a modest holding, the acquisition of 332 shares at $0 is a common practice for director compensation in many publicly traded companies.
  • This practice is similar to compensation structures observed at healthcare peers like Fresenius Medical Care (FMS) or Baxter International (BAX), where equity grants are a standard component of board remuneration packages to align interests with long-term shareholder value.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Insider OwnershipDirector Phyllis R. Yale increased her direct beneficial ownership of common stock by 332 shares.03/15/2026Enhances alignment of director's interests with shareholders, potentially improving corporate governance by linking personal wealth to company performance.

Related Party Transactions

  • The acquisition of 332 shares by Director Phyllis R. Yale from DaVita Inc. at a price of $0 represents a related party transaction, typical for equity compensation.

Stakeholder Impact

  • Shareholders: Potentially positive, as increased insider ownership can signal confidence and better alignment of interests between management and shareholders.

Key Dates

DateDescription
03/15/2026Date of common stock acquisition by Director Phyllis R. Yale.
03/17/2026Date the Form 4 was signed by Attorney-in-Fact.

Recommendation

hold

This Form 4 reports a routine insider acquisition of shares, likely an equity grant, which is a neutral to slightly positive event. It does not provide enough new, material information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate for existing investors.

Keywords

DaVita Inc., DVA, Insider Trading, Form 4, Stock Acquisition, Director, Equity Grant, Rule 10b5-1

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.